IL238244A0 - A modified release preparation for oprozomib - Google Patents
A modified release preparation for oprozomibInfo
- Publication number
- IL238244A0 IL238244A0 IL238244A IL23824415A IL238244A0 IL 238244 A0 IL238244 A0 IL 238244A0 IL 238244 A IL238244 A IL 238244A IL 23824415 A IL23824415 A IL 23824415A IL 238244 A0 IL238244 A0 IL 238244A0
- Authority
- IL
- Israel
- Prior art keywords
- oprozomib
- release formulations
- modified release
- modified
- formulations
- Prior art date
Links
- 108010064641 ONX 0912 Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 title 1
- 229950005750 oprozomib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717975P | 2012-10-24 | 2012-10-24 | |
| US201261721244P | 2012-11-01 | 2012-11-01 | |
| US201361793087P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/066679 WO2014066681A1 (en) | 2012-10-24 | 2013-10-24 | Modified release formulations for oprozomib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL238244A0 true IL238244A0 (en) | 2015-06-30 |
Family
ID=50485877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL238244A IL238244A0 (en) | 2012-10-24 | 2015-04-12 | A modified release preparation for oprozomib |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9295708B2 (enExample) |
| EP (1) | EP2912025A4 (enExample) |
| JP (1) | JP6505604B2 (enExample) |
| KR (1) | KR20150070406A (enExample) |
| CN (1) | CN104968650A (enExample) |
| AP (1) | AP3681A (enExample) |
| AR (1) | AR093126A1 (enExample) |
| AU (1) | AU2013334258A1 (enExample) |
| BR (1) | BR112015008572A2 (enExample) |
| CA (1) | CA2888039A1 (enExample) |
| CL (1) | CL2015001085A1 (enExample) |
| CR (1) | CR20150266A (enExample) |
| EA (1) | EA201590797A1 (enExample) |
| HK (2) | HK1215709A1 (enExample) |
| IL (1) | IL238244A0 (enExample) |
| IN (1) | IN2015DN03921A (enExample) |
| MX (1) | MX2015005069A (enExample) |
| PE (1) | PE20151051A1 (enExample) |
| PH (1) | PH12015500823A1 (enExample) |
| SG (1) | SG11201502849XA (enExample) |
| TN (1) | TN2015000135A1 (enExample) |
| TW (1) | TW201422255A (enExample) |
| UY (1) | UY35091A (enExample) |
| WO (1) | WO2014066681A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| CA2988918A1 (en) | 2015-06-19 | 2016-12-22 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| TWI751177B (zh) | 2016-06-29 | 2022-01-01 | 美商基澤生命科學公司 | 製備肽環氧酮免疫蛋白酶體抑制劑及其前驅體之方法 |
| JP2019529458A (ja) * | 2016-09-21 | 2019-10-17 | 小野薬品工業株式会社 | オプロゾミブ用の即放性製剤 |
| WO2018112078A1 (en) | 2016-12-14 | 2018-06-21 | Amgen Inc. | Gastro-retentive modified release dosage forms for oprozomib and process to make thereof |
| BR112020005079A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento de combinação para câncer |
| CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
| KR20250008774A (ko) | 2022-05-11 | 2025-01-15 | 셀진 코포레이션 | T 세포 요법 및 그의 생산과 관련된 방법 및 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| SI1360169T1 (sl) * | 2001-02-12 | 2007-12-31 | Wyeth Corp | Sukcinatna sol o-desmetil-venlafaksina |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| ES2628620T3 (es) * | 2005-11-09 | 2017-08-03 | Onyx Therapeutics, Inc. | Compuesto para inhibición de enzimas |
| EP1974725A4 (en) * | 2006-01-10 | 2012-12-05 | Kissei Pharmaceutical | PREPARATION WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| PL2207791T5 (pl) * | 2007-10-04 | 2020-07-27 | Onyx Therapeutics, Inc. | Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych |
| TWI504598B (zh) * | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
-
2013
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en not_active Ceased
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140113855A1 (en) | 2014-04-24 |
| CL2015001085A1 (es) | 2015-08-28 |
| JP2015535255A (ja) | 2015-12-10 |
| JP6505604B2 (ja) | 2019-04-24 |
| AU2013334258A1 (en) | 2015-04-30 |
| HK1215709A1 (zh) | 2016-09-09 |
| TN2015000135A1 (en) | 2016-10-03 |
| EP2912025A1 (en) | 2015-09-02 |
| BR112015008572A2 (pt) | 2017-07-04 |
| MX2015005069A (es) | 2015-07-17 |
| AP3681A (en) | 2016-04-19 |
| AR093126A1 (es) | 2015-05-20 |
| HK1208222A1 (en) | 2016-02-26 |
| WO2014066681A1 (en) | 2014-05-01 |
| EA201590797A1 (ru) | 2016-02-29 |
| AP2015008387A0 (en) | 2015-04-30 |
| CA2888039A1 (en) | 2014-05-01 |
| UY35091A (es) | 2014-05-30 |
| CR20150266A (es) | 2015-08-14 |
| CN104968650A (zh) | 2015-10-07 |
| IN2015DN03921A (enExample) | 2015-10-02 |
| EP2912025A4 (en) | 2016-06-08 |
| TW201422255A (zh) | 2014-06-16 |
| PH12015500823A1 (en) | 2015-06-22 |
| US20160213610A1 (en) | 2016-07-28 |
| US9295708B2 (en) | 2016-03-29 |
| SG11201502849XA (en) | 2015-05-28 |
| PE20151051A1 (es) | 2015-08-03 |
| KR20150070406A (ko) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201500212B (en) | Progesterone formulations | |
| IL234256B (en) | Tamper resistant immediate release formulations | |
| SI3117837T1 (sl) | Formulacije protiteles | |
| ZA201509340B (en) | Proliposomal testosterone formulations | |
| IL236304A0 (en) | Formulations for diclofenac | |
| ZA201202474B (en) | Controlled release compositions | |
| ZA201503603B (en) | Composition for immediate and extended release | |
| AP3681A (en) | Modified release formulations for oprozomib | |
| GB201500511D0 (en) | Brake | |
| EP4342536C0 (en) | BROMOCRIPTINE FORMULATIONS | |
| GB201210530D0 (en) | Extended release formulations | |
| EP2840704A4 (en) | RETARDER | |
| GB201110278D0 (en) | Formulations | |
| GB201221125D0 (en) | Pharmaceutial formulations | |
| GB201206178D0 (en) | Formulations | |
| IL220200A (en) | Release device | |
| HUP1100207A2 (en) | Modified release composition | |
| GB201104049D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations | |
| GB201105410D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201102795D0 (en) | Formulations | |
| GB201105360D0 (en) | Formulations | |
| GB201104048D0 (en) | Formulations | |
| GB201111578D0 (en) | Pharmeutical formulations |